Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8137121 | 0.95 | MAPT (0.42) | MAPTF2RL3MEN1KMT2ALMNA | |
| SCHEMBL8559970 | 0.85 | MAPT (0.37) | MAPTF2RL3MEN1KMT2ALMNA | |
| SCHEMBL8019238 | 0.84 | HTT (0.34) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7988881 | 0.73 | FTO (0.47) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL7985195 | 0.72 | CDK4 (0.38) | MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL9401951 | 0.72 | FTO (0.61) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL9138317 | 0.72 | FTO (0.61) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL9137157 | 0.72 | FTO (0.61) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL8030532 | 0.70 | SIRT1 (0.43) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL9078081 | 0.70 | FTO (0.41) | MAPTMEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6300340-B1 | USEFUL FOR THERAPY OF CANCER AND SOLID TUMORS | ADIR ET COMPAGNIE (FR) | 2001-10-09 | — | — | US | disclosed |
| US-6162822-A | Bisimide compounds | ADIR ET COMPAGNIE (FR) | 2000-12-19 | — | — | US | disclosed |